JP2023503846A5 - - Google Patents
Info
- Publication number
- JP2023503846A5 JP2023503846A5 JP2022527957A JP2022527957A JP2023503846A5 JP 2023503846 A5 JP2023503846 A5 JP 2023503846A5 JP 2022527957 A JP2022527957 A JP 2022527957A JP 2022527957 A JP2022527957 A JP 2022527957A JP 2023503846 A5 JP2023503846 A5 JP 2023503846A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- binding protein
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025167073A JP2026026484A (ja) | 2019-11-15 | 2025-10-03 | 二重パラトープ性ｃｄ７３抗体 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962936119P | 2019-11-15 | 2019-11-15 | |
| US62/936,119 | 2019-11-15 | ||
| US202063023542P | 2020-05-12 | 2020-05-12 | |
| US63/023,542 | 2020-05-12 | ||
| US202063086982P | 2020-10-02 | 2020-10-02 | |
| US63/086,982 | 2020-10-02 | ||
| PCT/US2020/060434 WO2021097223A2 (en) | 2019-11-15 | 2020-11-13 | Biparatopic cd73 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025167073A Division JP2026026484A (ja) | 2019-11-15 | 2025-10-03 | 二重パラトープ性ｃｄ７３抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023503846A JP2023503846A (ja) | 2023-02-01 |
| JP2023503846A5 true JP2023503846A5 (https=) | 2023-11-17 |
| JP7789667B2 JP7789667B2 (ja) | 2025-12-22 |
Family
ID=73790235
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022527957A Active JP7789667B2 (ja) | 2019-11-15 | 2020-11-13 | 二重パラトープ性ｃｄ７３抗体 |
| JP2025167073A Pending JP2026026484A (ja) | 2019-11-15 | 2025-10-03 | 二重パラトープ性ｃｄ７３抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025167073A Pending JP2026026484A (ja) | 2019-11-15 | 2025-10-03 | 二重パラトープ性ｃｄ７３抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220403041A1 (https=) |
| EP (1) | EP4058150A2 (https=) |
| JP (2) | JP7789667B2 (https=) |
| KR (1) | KR20220100929A (https=) |
| CN (1) | CN115003385A (https=) |
| AU (1) | AU2020384305A1 (https=) |
| BR (1) | BR112022009317A2 (https=) |
| CA (1) | CA3161717A1 (https=) |
| CO (1) | CO2022008204A2 (https=) |
| IL (1) | IL292959A (https=) |
| MX (1) | MX2022005866A (https=) |
| PH (1) | PH12022551150A1 (https=) |
| WO (1) | WO2021097223A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY204117A (en) | 2017-06-22 | 2024-08-08 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| PE20221409A1 (es) | 2020-01-03 | 2022-09-20 | Incyte Corp | Anticuerpos anti-cd73 y usos de estos |
| TW202135823A (zh) | 2020-01-03 | 2021-10-01 | 美商英塞特公司 | Ｃｄ７３抑制劑及ａ２ａ／ａ２ｂ腺苷受體抑制劑組合療法 |
| JP2025512384A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| JP2025521231A (ja) * | 2022-06-08 | 2025-07-08 | シャンハイ フアオタ バイオファーマシューティカル カンパニー、リミテッド | Ｃｄ７３抗体カクテル療法 |
| CN115991772B (zh) * | 2022-08-12 | 2023-09-01 | 南京蓬勃生物科技有限公司 | 抗cd73抗体或其抗原片段及其应用 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| EP1212422B1 (en) * | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US8460364B2 (en) | 2006-07-20 | 2013-06-11 | Orbusneich Medical, Inc. | Bioabsorbable polymeric medical device |
| ES2593484T3 (es) | 2007-03-29 | 2016-12-09 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| JP6385357B2 (ja) | 2012-11-27 | 2018-09-05 | アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ | 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途 |
| EP3204417B1 (en) * | 2014-10-10 | 2020-07-22 | Innate Pharma | Cd73 blockade |
| GB2537445A (en) * | 2014-11-10 | 2016-10-19 | Medimmune Ltd | Binding molecules specific for CD73 and uses thereof |
| WO2016082044A1 (en) | 2014-11-27 | 2016-06-02 | Zymeworks Inc. | Methods of using bispecific antigen-binding constructs targeting her2 |
| WO2017118613A1 (en) * | 2016-01-08 | 2017-07-13 | Syddansk Universitet | Bispecific antibodies targeting human cd73 |
| EP3423494A1 (en) * | 2016-03-04 | 2019-01-09 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
| WO2018013611A1 (en) * | 2016-07-11 | 2018-01-18 | Corvus Pharmaceuticals, Inc. | Anti-cd73 antibodies |
| CA3045376C (en) * | 2017-01-24 | 2022-08-30 | I-Mab | Anti-cd73 antibodies and uses thereof |
| EP3609580A4 (en) * | 2017-04-09 | 2021-03-24 | Combio Pharmaceutical, Inc. | COMMON LIGHT CHAIN BIPARATOPIC AND MULTIPARATOPIC ANTIBODIES AND METHOD OF USE |
| US11530273B2 (en) * | 2017-05-23 | 2022-12-20 | Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing |
| MY204117A (en) * | 2017-06-22 | 2024-08-08 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| EP3642240A1 (en) * | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
| EP3762030A4 (en) * | 2018-03-09 | 2022-01-05 | Phanes Therapeutics, Inc. | ANTI-CD73 ANTIBODIES AND USES THEREOF |
| WO2019173692A2 (en) * | 2018-03-09 | 2019-09-12 | Agenus Inc. | Anti-cd73 antibodies and methods of use thereof |
| TWI869346B (zh) * | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
-
2020
- 2020-11-13 CA CA3161717A patent/CA3161717A1/en active Pending
- 2020-11-13 WO PCT/US2020/060434 patent/WO2021097223A2/en not_active Ceased
- 2020-11-13 PH PH1/2022/551150A patent/PH12022551150A1/en unknown
- 2020-11-13 BR BR112022009317A patent/BR112022009317A2/pt unknown
- 2020-11-13 IL IL292959A patent/IL292959A/en unknown
- 2020-11-13 JP JP2022527957A patent/JP7789667B2/ja active Active
- 2020-11-13 MX MX2022005866A patent/MX2022005866A/es unknown
- 2020-11-13 EP EP20821493.2A patent/EP4058150A2/en active Pending
- 2020-11-13 CN CN202080092714.3A patent/CN115003385A/zh active Pending
- 2020-11-13 AU AU2020384305A patent/AU2020384305A1/en active Pending
- 2020-11-13 US US17/775,446 patent/US20220403041A1/en active Pending
- 2020-11-13 KR KR1020227019869A patent/KR20220100929A/ko active Pending
-
2022
- 2022-06-10 CO CONC2022/0008204A patent/CO2022008204A2/es unknown
-
2025
- 2025-10-03 JP JP2025167073A patent/JP2026026484A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023503846A5 (https=) | ||
| JP7050115B2 (ja) | 抗ＦｃＲｎ抗体 | |
| JP2024510098A5 (https=) | ||
| JP2023509448A5 (https=) | ||
| RU2608644C2 (ru) | Антитела против белка рецептора с-мет | |
| RU2609627C2 (ru) | Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh | |
| JP7841846B2 (ja) | Ｆｘ活性化を促進する第ｘ因子結合剤 | |
| JP2005518789A5 (https=) | ||
| WO2019115674A1 (en) | Anti-alpha-synuclein antibodies | |
| JP2022521411A (ja) | 抗ｃｄ３９抗体および抗ｐｄ－１または抗ｐｄ－ｌ１抗体を伴う併用療法 | |
| JP2022500455A5 (https=) | ||
| CN109721656B (zh) | 靶向rankl的治疗性抗体 | |
| JP2023511376A5 (https=) | ||
| JP6901402B2 (ja) | 単量体抗体Ｆａｂ−ｄｓＦｖ多量体種のパーセンテージを増加させる方法 | |
| JP2025508317A5 (https=) | ||
| JP2025529812A (ja) | 甲状腺刺激ホルモン受容体に結合する抗体及びその使用 | |
| JP2025500796A5 (https=) | ||
| CN110494447B (zh) | 使用抗人gpv1抗体抑制血小板聚集 | |
| JP2023518408A5 (https=) | ||
| JP2021529524A5 (https=) | ||
| JP2023530675A (ja) | ヒト疾患の治療のためのｃｄ３８抗体 | |
| WO2024225446A1 (ja) | 新規なＮａｖ１．７モノクローナル抗体を含む医薬組成物 | |
| WO2023074888A1 (ja) | 新規なＮａｖ１．７モノクローナル抗体 | |
| RU2025110616A (ru) | CD163 Связывающий белок | |
| RU2025109632A (ru) | Антитела, которые связывают cd228 |